Prof Feugier speaks with ecancer at EHA 23 about results from a phase II trial of treating CLL with induction obinutuzumab and ibrutinib.

He describes how CR with undetectable residual disease (uMRD) may be associated with a longer survival in CLL.

With a manageable toxicity profile, 48% CR rate and 12.5% uMRD at 9 months, Prof Feugier describes the need for further research and further rounds of immunochemotherapy to fully induce uMRD.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.